Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)

Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs

IgG4-RD is the first of several potential disease indications to be pursued for obexelimab given its unique non-depleting, B-cell inhibition

WALTHAM, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies, today announced that the first patient has been dosed in the INDIGO Phase 3 registrational study of obexelimab. The INDIGO study will evaluate the clinical efficacy and safety of obexelimab treatment in the prevention of IgG4-related disease (IgG4-RD) flare. Obexelimab is a high-affinity bifunctional antibody that inhibits B-cell lineages by simultaneously binding to CD19 and FcƳRIIB, thereby downregulating B-cell activity in patients with autoimmune diseases associated with autoantibodies, such as IgG4-RD.

“IgG4-RD is a chronic and serious fibroinflammatory condition that can affect nearly any organ system and can have a profound impact on many patients, leading to severe organ damage or death,” said Hua Mu, M.D., Ph.D., Chief Executive Officer at Zenas. “There are no currently approved treatments for patients living with IgG4-RD. Based upon the promising data from a Phase 2 study of obexelimab in IgG4-RD patients, we are excited to continue to evaluate the potential of obexelimab in the INDIGO study.”

About the INDIGO Study

The INDIGO study is a global multicenter, randomized, double-blind, placebo-controlled study enrolling up to 200 adults with active IgG4-RD signs/symptoms (i.e., flare) that require steroid therapy. Patients will be randomized in a ratio of 1:1 to receive either obexelimab or placebo, administered as subcutaneous injections.

The primary endpoint of INDIGO is time to first IgG4-RD flare (defined as the reappearance of previous signs/symptoms or appearance of new signs/symptoms of IgG4-RD) that requires initiation of rescue therapy from randomization to Week 52. Safety will be evaluated throughout the study duration.

More information on the INDIGO study (NCT05662241) is available at clinicaltrials.gov.

About Obexelimab

Obexelimab is an investigational Phase 3-stage, novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19. Simultaneous binding to CD19 and FcƳRIIB by obexelimab mimics a natural antigen-antibody complex and downregulates B cell activity. In several early-stage clinical studies, 198 subjects were treated with obexelimab. In these clinical studies, the molecule demonstrated effective inhibition of B cell function without depleting the cells and generated an encouraging treatment effect in patients with multiple autoimmune diseases. Zenas acquired exclusive worldwide rights to obexelimab from Xencor, Inc.

About IgG4-RD

IgG4-RD is a chronic and serious fibroinflammatory disease typically affecting multiple organs (e.g., pancreas, liver, kidney, bile duct, salivary and lacrimal glands). Approximately 20,000 people are diagnosed with IgG4-RD in the US, with similar prevalence rates across geographies. Many patients have some degree of irreversible organ damage at the time of diagnosis. Although nearly all patients initially respond to glucocorticoid (GC) therapy, a majority of patients will relapse/flare within a few months of discontinuing treatment, requiring rescue therapy. Chronic GC therapy is also associated with toxicity in many patients.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients around the world. With clinical development and operations globally, Zenas is advancing a deep and balanced global portfolio of potential first- and best-in-class autoimmune therapeutics in areas of high unmet medical need while meeting the value requirements of the dynamic global healthcare environment. The company’s pipeline continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those living with autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer, President & COO
Zenas BioPharma
IR@zenasbio.com

GlobeNewswire Distribution ID 8727743

Nikkiso Clean Energy & Industrial Gases Group Announces their First On-Site FAT Testing at their Marine Facility in Busan, Korea

TEMECULA, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) — Nikkiso Clean Energy & Industrial Gases Group (“Group”), a part of the Nikkiso Co., Ltd (Japan) group of companies, is proud to announce its first on-site FAT testing at their new Marine facility in Busan, Korea. This accomplishment exemplifies their commitment to and support of the growth of the Korean market.

Since July 2022, they have been fabricating high-pressure pump skids in the 4,000 square meter facility. With the successful completion of this FAT test for Hapag Lloyd AG (for the largest fuel gas supply system), they demonstrate the capabilities of their factory and its LN2 (liquid nitrogen) test facility. This facility continues to provide the commissioning and maintenance support previously provided. With the HP pumps skid fabrication and testing capabilities, they now provide full-system marine solutions to their customers.

The FAT test is mandatory prior to skid delivery, which tests for overall performance (i.e., pump maximum flowrate, vaporizer performance, lube-oil (LO) system, nitrogen purge system, cryogenic valves, etc.). It must be witnessed by shipowner, class society, and customers, verifying the product meets its performance requirements.

According to Jay Lee, General Manager, Korea, “Nikkiso ACD has been the preferred supplier for Fuel Gas skids to the Korean shipbuilding industry for over 20 years! With our new skid packaging and testing facility located near the shipyards in Korea, we now have even greater capacity to provide local support and meet the significant global marine demands.”

“This is an important next step for our Group and the LNG powered Marine market, and an expanded benefit for our Marine customers. Nikkiso CE&IG will now be able to provide and test full systems and support our customers with a turnkey system solution,” according to Peter Wagner, CEO of Cryogenic Industries and President of the Group.

Contact Information:
Nikkiso Clean Energy and Industrial Gases – Korea
Head Office & Factory: 83, Nosansanupjung-ro, Gangseo-gu, Busan, 46752, Korea
Branch office: #1912, 170, Gwanggyojungang-ro, Yeongtong-gu, Suwon, Gyeonggi-do, 16614, Korea
info@NikkisoCEIG-Korea.com

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture and service engineered cryogenic gas processing equipment (pumps, turboexpanders, heat exchangers, etc.) and process plants for Industrial Gases, and Natural Gas Liquefaction (LNG), Hydrogen Liquefaction (LH2) and Organic Rankine Cycle for Waste Heat Recovery. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Nikkiso Cryo, Nikkiso Integrated Cryogenic Solutions, Cosmodyne and Cryoquip and a commonly controlled group of 20 operating entities.

For more information, please visit www.nikkisoCEIG.com and www.nikkiso.com.

MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

GlobeNewswire Distribution ID 8727431

FURA Gems Appoints Mazars SA and Initiates the Process for Responsible Jewellery Council (RJC) Registration

FURA Gems

Ruby, Emerald and Sapphire from FURA Gems

DUBAI, United Arab Emirates, Jan. 11, 2023 (GLOBE NEWSWIRE) — FURA Gems announced today it had initiated the certification process with the RJC, demonstrating its commitment to responsible business practices. The project will be headed by Mazars Switzerland, which will accompany FURA Gems and all its operating mining locations in Colombia for emeralds, Mozambique for rubies, and Australia for sapphire through the process of RJC preparation. FURA has already registered its Australian location with RJC, and FURA will now look to expand the certification for the group and all its operating sites. With Mazar’s support, FURA will target to complete the certification process on or before December 31, 2023, for all its operating locations.

The certification with RJC is part of the ambitious ESG strategy deployed by FURA since its foundation in 2017. Earlier last year, FURA announced the partnership with Gübelin to provide traceability for all its stones through the Provenance Proof Blockchain. RJC Certification marks an additional important step towards achieving FURA’s ambitious ESG goals.

“This is a strong statement from our side, as we launch certification of all our mines producing emeralds, rubies and sapphires,” says Dev Shetty, Founder & CEO of FURA Gems. “The certification process will enable us to formalize our commitment since our foundation: to provide the jewellery market with traceable, sustainably sourced colour gemstones. To achieve this, we have identified Mazars as the ideal partner to conduct the process throughout our production sites and at the headquarters level. Mazars offers the ideal combination of regional expertise and global perspective, enabling us to conduct the project with the greatest level of competencies & professionalism.”

Franck Paucod, Partner at Mazars, explains, “We are thrilled to accompany FURA Gems through the demanding process of RJC COP Certification. Conducting the project for the three (3) mines simultaneously shows FURA’s commitment to responsible mining. We are confident that with our experiences in the gems and jewellery sector, we will be able to support FURA with its commitment to building the solid framework to achieve the RJC certification.”

ABOUT FURA GEMS

FURA Gems Inc. is a coloured gemstone mining and marketing company established in 2017. Headquartered in Dubai, United Arab Emirates, FURA has over 1,200 employees across continents. It is the first pioneering, creative and ethical enterprise to cover the entire spectrum of coloured gemstones. It operates three mining subsidiaries in Colombia, Mozambique, and Australia that mines emeralds, rubies, and sapphires. FURA also initiated its exploration program in Madagascar for sapphire mining. It is the fastest-growing coloured gemstone mining company to ensure the stability and traceability of ethically mined coloured gemstones from rough to retail.

ABOUT MAZARS

Mazars is an internationally integrated partnership, specialising in audit, accountancy, advisory, tax and legal services. Operating in over 90 countries and territories around the world, Mazars draws on the expertise of more than 44,000 professionals to assist clients of all sizes at every stage in their development.

Mazars Switzerland is specialised in the watch & jewellery industry. Mazars can either accompany clients throughout the RJC Code of Practice COP certification preparation and registration which is the case for FURA Gems or perform audits for the certification of companies in conformity of the RJC COP.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/80695a84-8e96-48d7-a21d-6548f0e035e7

FURTHER INFORMATION

Gianluca Maina, Marketing Director, FURA Gems, gianluca.maina@furagems.com

Franck Paucod, Partner, Mazars SA, franck.paucod@mazars.ch

GlobeNewswire Distribution ID 1000776648

Conagen starts first commercial production of sustainable Tyrian purple for textile dye

New era for green tech alternatives to replace petrochemical synthesized dyes.

Bedford, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) — Conagen announced the successful scale-up of its sustainable, cost-effective Tyrian purple, a historically coveted and expensive dye found in rare and limited sources in marine nature.

Conagen is the world’s first and only biotechnology company commercializing a sustainable Tyrian purple by fermentation. As with any biologically-sourced textile dye, this color-fast compound reduces pollution and carbon footprints when used as an alternative to petrochemically synthesized dyes commonly used in the textiles industry today.

Also known as Phoenician purple, royal purple, imperial purple, or imperial dye, this rare dye dates back several millennia to the bronze age when the Phoenicians from Tyre, Lebanon, on the Levantine coast, produced it for the ancient Greeks, Persians, Byzantines, and the Roman empire to clad emperors and kings with luxury textiles. Tyrian purple was once worth more than its weight in gold for its prized deep rich purple. In 301 CE, during the Roman Empire, one pound of Tyrian purple dye was priced at approximately three Troy pounds of gold, roughly $66,000 in today’s currency.

Current producers extract and harvest Tyrian purple from the murex shellfish in much the same way as the ancient Phoenicians. Thousands — approximately 10,000 or (54 kilograms (119 lb.) of these predatory sea snails are required to make diminishing quantities of Tyrian purple to produce 1 gram of the dye, making it impracticable, expensive, and environmentally unfriendly. Ancient dye producers all but drove the murex species to extinction along the coasts of Phoenicia, evident in the vast deposits of the shells excavated on the outskirts of Sidon, Tyre, and across the Mediterranean.

Conagen’s Tyrian purple, produced by precision fermentation and bioconversion, is a natural, sustainable dye ideal for textile companies under pressure to deliver fashions more sustainably and with a reduced global environmental footprint, especially from manufacturing.

“Conagen is democratizing the exclusive use of a color once reserved for royalty — now obtainable on a global scale,” said Casey Lippmeier, Ph.D., senior vice president of innovation. “Our fermentation and bioconversion technologies enable us to offer true-to-nature products. By leveraging Conagen’s bioengineering and commercial manufacturing capabilities, we’re unlocking Tyrian purple’s great potential as an accessible and sustainable dye. We expect Tyrian purple to inspire fresh ideas in multiple industries, making this rare and exciting color more marketable with planet-conscious consumers.”

The Tyrian purple technology is based on two of Conagen’s many key bioengineering platforms, which enable accelerated product development timelines for its competitive phenolics, terpenoids, proteins, and peptide molecules.

As an example, Conagen’s phenolics platform was used to make an important antioxidant, hydroxytyrosol, the active health ingredient found in oil, juice, and fruit in olives. Using another platform, Conagen has optimized the production of different amino acid-based products, including the nutraceutical antioxidant ergothioneine, a “longevity vitamin” currently branded as “Ergoactive” by Conagen’s pipeline partner Blue California. To produce the Tyrian purple, Conagen drew from both proprietary platforms to develop novel enzymes which increase the conversion efficiency of precursors to the dye.

“Conagen has further solidified its leadership in the bioeconomy by rapidly producing multiple novel and interesting molecules, such as Tyrian purple,” said Lippmeier. “Our technology platforms have been meticulously engineered and improved upon for over a decade, and they are extremely efficient at making targeted compounds from an expanding array of molecular classes for our internal product development and collaborative ventures.”

Conagen aims to replace petroleum-based ingredients and reduce carbon footprints with green technologies. Tyrian purple adds to Conagen’s natural color offerings, including several carotenoids made by fermentation which have been scaled to global production. As a dye, Tyrian purple is ideal for textile fabrics, clothing, handbags, and related accessories.

About Conagen

Conagen is making the impossible possible. Our scientists and engineers use modern synthetic biology tools to program micro-organisms and enzymes on a molecular level to produce high-quality, sustainable, natural products manufactured worldwide via precision fermentation and bioconversion. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceuticals, and renewable materials.

Attachments

Ana Arakelian, Head of Public Relations and Communications
Conagen
+1-781-271-1588
ana.arakelian@conagen.com

GlobeNewswire Distribution ID 8725973

Hitachi Energy awarded major orders to integrate two large offshore wind farms with Poland’s power grid

Grid connection and power quality solution for the MFW Baltyk II and MFW Baltyk III offshore wind farms will help Poland progress towards its renewable energy goal and provide emission-free electricity for more than 2 million Polish homes.

Zurich, Switzerland, Jan. 09, 2023 (GLOBE NEWSWIRE) — Zurich, Switzerland, January 9, 2023 – Hitachi Energy, a global technology leader that is advancing a sustainable energy future for all, today announced it has won two major orders from Equinor and Polenergia to provide an AC grid connection and power quality solution for their jointly owned MFW Baltyk II and MFW Baltyk III offshore wind farms, with a combined generating capacity of 1,440 megawatts in the Polish sector of the Baltic Sea.

Hitachi Energy will provide each of the two wind farms with an offshore grid connection that will receive the power from the wind turbines and transfer it to shore, a mainland grid connection that will transmit the power into the national transmission system, and a STATCOM power quality solution to ensure that power flows reliably and stably at optimal capacity and at all times, despite the often high variability of wind power.

MFW Baltyk II and MFW Baltyk III are pending a final investment decision in 2024, and are scheduled to deliver first power in 2027. They will be one of the first offshore wind farms in Poland and part of the country’s ambitious program to develop its offshore wind potential and increase the use of renewables in its electricity mix, which historically is dominated by coal. The government aims to have around 11 gigawatts of offshore wind capacity either operational or under development by 20271.

Hitachi Energy was selected in a competitive procurement process on the strength of its front-end engineering and design (FEED) studies and optimized solutions, its long track record of project execution excellence, and its close working relationships over many decades with Equinor and PSE (Poland’s transmission system operator) and, most recently, Polenergia.

“Integrating large-scale renewable energy sources with the power grid is a key enabler of the energy transition and a field in which we have been a pioneer for decades,” said Niklas Persson, Managing Director of Hitachi Energy’s Grid Integration business. “Our grid connection technologies feature in offshore wind farms worldwide, and our power quality solutions resolve bottlenecks and keep the voltage stable and the energy flowing in power systems globally.”

These project awards further underscore Hitachi Energy’s position as a global leader in the offshore wind market and the partner of choice for wind farm developers, combining solid experience with grid technologies to help make the world’s energy system more sustainable, flexible and secure by enabling new solutions and business models to be deployed at scale and with speed.

The company has been continuously developing its portfolio to better serve this market with the recent launch of its Grid-eXpand™ range of modular and prefabricated grid connection solutions that make it faster, simpler and more efficient to connect offshore wind farms to mainland grids, and with its complete portfolio of STATCOMs and E-STATCOMs for all power ranges, ensuring grid stability and power quality at all times.

The announcement follows a recent global agreement between Hitachi Energy and Equinor to collaborate on high-voltage transmission systems (AC and DC) to connect Equinor offshore wind farms and production facilities to mainland power grids worldwide.

1Global Wind Energy Council – Global Offshore Wind Report 2022

About Hitachi Energy Ltd.

Hitachi Energy is a global technology leader that is advancing a sustainable energy future for all. We serve customers in the utility, industry and infrastructure sectors with innovative solutions and services across the value chain. Together with customers and partners, we pioneer technologies and enable the digital transformation required to accelerate the energy transition towards a carbon-neutral future. We are advancing the world’s energy system to become more sustainable, flexible and secure whilst balancing social, environmental and economic value. Hitachi Energy has a proven track record and unparalleled installed base in more than 140 countries. Headquartered in Switzerland, we employ around 40,000 people in 90 countries and generate business volumes of approximately $10 billion USD.

https://www.hitachienergy.com

https://www.linkedin.com/company/hitachienergy

https://twitter.com/HitachiEnergy

About Hitachi, Ltd.

Hitachi drives Social Innovation Business, creating a sustainable society with data and technology. We will solve customers’ and society’s challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products, under the business structure of Digital Systems & Services, Green Energy & Mobility, Connective Industries and Automotive Systems. Driven by green, digital, and innovation, we aim for growth through collaboration with our customers. The company’s consolidated revenues for fiscal year 2021 (ended March 31, 2022) totaled 10,264.6 billion yen ($84,136 million USD), with 853 consolidated subsidiaries and approximately 370,000 employees worldwide. For more information on Hitachi, please visit the company’s website at https://www.hitachi.com.

Attachment

Jocelyn Chang
Hitachi Energy
+41793847775
jocelyn.chang@hitachienergy.com

GlobeNewswire Distribution ID 8725982

Nikkiso Clean Energy & Industrial Gases Group Acquires Cryotec Anlagenbau GmbH, Wurzen, Germany

TEMECULA, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) — Nikkiso Cryogenic Industries’ Clean Energy and Industrial Gases Group (“Group”), a part of Nikkiso Co., Ltd (Japan), has entered into an agreement to acquire Cryotec Anlagenbau GmbH, (Wurzen close to Leipzig, Saxony, Germany) for an undisclosed amount.

A global plant engineering and construction company, Cryotec provides planning, project management, manufacturing and engineering services of skid-mounted/containerized air separation and liquefaction plants, and CO2 technologies offering tailored solutions to their customers.

Cryotec will operate as part of the Group’s GmbH facility, based in Neuenburg am Rhine, Germany. The Group consists of six functional business units: Cryogenic Pumps, Heat Exchanger Systems, Process Systems, Fueling & Solutions, Energy Infrastructure & Strategic Projects and Service.

“Our acquisition of Cryotec will allow the Group to expand our footprint in Europe, and broaden our expertise in carbon capture and biogas technologies”, according to Ole Jensen, Vice President, Europe.

“We look forward to bringing Cryotec into our Nikkiso family. This acquisition exemplifies our passion to provide, efficient, performance-based products and service,” according to Peter Wagner, CEO of Cryogenic Industries and President of the Group.

This acquisition represents their commitment to and support of the European market. The acquisition is expected to close during Q1, 2023

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture, and service engineered cryogenic gas processing equipment (pumps, turboexpanders, heat exchangers, etc.), and process plants for Industrial Gases, Natural gas Liquefaction (LNG), Hydrogen Liquefaction (LH2) and Organic Rankine Cycle for Waste Heat Recovery. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Nikkiso Cryo, Nikkiso Integrated Cryogenic Solutions, Cosmodyne and Cryoquip and a commonly controlled group of approximately 20 operating entities.

For more information, please visit www.NikkisoCEIG.com and www.nikkiso.com.

MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

GlobeNewswire Distribution ID 8725755

Zoom Appoints Cindy Hoots to Board of Directors

SAN JOSE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) announced that it has appointed Cindy Hoots, Chief Digital Officer and CIO of AstraZeneca, as an independent director on Zoom’s Board of Directors effective immediately.

“Zoom has changed the way companies around the world do business and is ushering in entirely new ways to transact business internationally,” said Hoots. “Global leaders have the responsibility to ensure our ecosystem of employees, partners, customers, and our community can connect and collaborate seamlessly in a sustainably responsible way. I am thrilled to join Zoom’s Board and CEO Eric Yuan, an inspirational leader with a strong vision. I believe this company has an important role in making a meaningful impact on people’s lives.”

“On behalf of Zoom’s Board of Directors, I am excited to welcome Cindy to the team,” said Zoom Founder and CEO Eric S. Yuan. “Cindy’s experience leading large global companies in highly regulated and complex industries will bring tremendous value to our company. As Zoom continues to grow and innovate within the healthcare sector, we look forward to Cindy’s perspectives and contributions.”

About Cindy Hoots
Ms. Hoots has served as the Chief Digital Officer and Chief Information Officer at AstraZeneca PLC, a pharmaceutical company, since January 2020. From January 2018 to December 2019, she served as Global Vice President of Technology of Unilever PLC, a multinational consumer goods company. Prior to joining Unilever, Ms. Hoots served as Vice President of Next Generation Products, Commercial, and Digital Transformation at British American Tobacco plc from 2016 to 2018. She also spent 16 years at Mars, Incorporated. Ms. Hoots received a B.S. in Computer Information Systems from DeVry Institute of Technology.

About Zoom
Zoom is for you. Zoom is a space where you can connect to others, share ideas, make plans, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for individuals, small businesses, and large enterprises alike. Founded in 2011, Zoom is publicly traded (NASDAQ: ZM) and headquartered in San Jose, California. Visit zoom.com and follow @zoom.

Zoom PR
Colleen Rodriguez
Head of Global PR
press@zoom.us

GlobeNewswire Distribution ID 8724219

Duck Creek to acquire Imburse Payments, a modern payments platform

Strategic acquisition will add digital, out-of-the box payments capabilities to Duck Creek’s comprehensive suite of SaaS solutions for P&C and general insurers

Boston, MA, Jan. 05, 2023 (GLOBE NEWSWIRE) — Duck Creek Technologies (NASDAQ: DCT) (“Duck Creek”), the intelligent solutions provider defining the future of property and casualty (P&C) insurance, today announced a definitive agreement to acquire Imburse Payments (“Imburse”), a Swiss-based modern payments platform.

Imburse’s cloud-native software-as-a-service (SaaS) payment solution is built for the insurance industry. The modern payments platform brings greater ease and efficiency into end-to-end insurance transactions. Imburse enables insurance carriers to quickly connect to the entire payments ecosystem at a lower cost, seamlessly integrate with existing finance infrastructure and processes, and manage multiple partners for collections and disbursements, all in one place. The platform is consumer friendly and provides policyholders with both an easy-to-use, flexible payments experience and the ability to quickly and securely direct payments.

As part of Duck Creek, Imburse will continue to serve its existing client base and markets, while accelerating expansion plans for new clients across Europe and into North America and Asia-Pacific. The Imburse platform will continue to be available on a stand-alone basis and will also be fully integrated with Duck Creek’s suite of technology solutions, further enabling carriers’ digital transformation goals with modern tools.

“Imburse has developed a great product for the global insurance industry that is not only easy to integrate and implement, but also gives carriers incredible flexibility and payment choices,” said Mike Jackowski, CEO of Duck Creek Technologies. “Imburse has a strong team that embodies Duck Creek’s core values. They have deep expertise across the payments ecosystem and will help to broaden Duck Creek’s insurance industry leadership.”

“Being part of Duck Creek will further accelerate our mission to simplify how businesses around the world access the global payments ecosystem,” said Oliver Werneyer, CEO of Imburse. “We are excited to be part of Duck Creek and to work jointly to deliver modern technology innovations that transform the insurance industry for the future.”

The acquisition remains subject to customary closing conditions and is expected to close during the second fiscal quarter of 2023.

Conference Call Information

Duck Creek Technologies will host a conference call today, January 5, 2023, at 5:00 p.m. (Eastern Time) to discuss Duck Creek’s financial results and business outlook, as well as the proposed acquisition of Imburse Payments. A live webcast of the call will be available on the “Investor Relations” page of the Duck Creek’s website at https://ir.duckcreek.com/. To access the call by phone, please go to this link (registration link), and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time at https://ir.duckcreek.com/.

About Imburse Payments

Imburse is a modern payments platform built for insurers. Via a single connection, directly or through a current core system provider, insurance carriers can access the entire global payment ecosystem to collect or pay-out using any technology, any provider, in any market.

About Duck Creek Technologies

Duck Creek Technologies (NASDAQ: DCT) is the intelligent solutions provider defining the future of the property and casualty (P&C) and general insurance industry. We are the platform upon which modern insurance systems are built, enabling the industry to capitalize on the power of the cloud to run agile, intelligent, and evergreen operations. Authenticity, purpose, and transparency are core to Duck Creek, and we believe insurance should be there for individuals and businesses when, where, and how they need it most. Our market-leading solutions are available on a standalone basis or as a full suite, and all are available via Duck Creek OnDemand. Visit www.duckcreek.com to learn more. Follow Duck Creek on our social channels for the latest information – LinkedIn and Twitter.

Attachment

Drake Manning
Duck Creek Technologies
drake.manning@duckcreek.com

Carley Bunch
Duck Creek Technologies
carley.bunch@duckcreek.com

Michael Sharp
Imburse Payments
michael.sharp@imbursepayments.com

GlobeNewswire Distribution ID 8724246